Researchers at Rutgers University are developing a new oral COVID-19 treatment, Jun12682, which has shown potential in animal studies to supplement or replace Paxlovid. This novel drug targets a key viral protein and does not interfere with other medications, offering significant advantages over current treatments.
Rutgers researchers are advancing a potential new COVID-19 treatment, Jun12682, which is effective in animal studies and compatible with other medications, unlike the current leading treatment, Paxlovid.
Researchers at Rutgers believe they are among the lead in developing an oral DOI: 10.1126/science.adm9724